You are here

Article Text

Article menu
Download PDFPDF
Brief communication
Bronchiectasis severity correlates with outcome in patients with primary antibody deficiency
  1. Jimstan Periselneris1,
  2. Silke Schelenz2,
  3. Michael Loebinger3,
  4. Patricia Macedo1,
  5. Zoe Adhya4,
  6. Darius Armstrong-James5,
  7. W Peter Kelleher6
  1. 1 Respiratory Medicine, King's College Hospital NHS Foundation Trust, London, UK
  2. 2 Microbiology, King's College Hospital NHS Foundation Trust, London, UK
  3. 3 Host Defence Unit, Division of Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK
  4. 4 Immunology, King's College Hospital NHS Trust, London, UK
  5. 5 Department of Infectious Diseases, Imperial College London, London, UK
  6. 6 Immunology, Imperial College London, London, UK
  1. Correspondence to Dr Jimstan Periselneris, Respiratory Medicine, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK; jperiselneris{at}nhs.net

Abstract

Bronchiectasis is a well-recognised complication of primary antibody deficiency (PAD) syndromes. Previous data suggest that mortality in common variable immune deficiency (CVID) is not associated with isolated bronchiectasis. A retrospective analysis of patients with CVID and specific antibody deficiency in two tertiary referral centres with lung disease was conducted. Severity of bronchiectasis at presentation was associated with mortality. Lower FEV1, colonisation with Pseudomonas aeruginosa and a diagnosis of COPD were also associated with mortality. Bronchiectasis is an important driver of mortality in patients with PAD syndromes.

  • bronchiectasis
  • immunodeficiency

http://dx.doi.org/10.1136/thoraxjnl-2020-215585

Statistics from Altmetric.com

    View Full Text

    Footnotes

    • Twitter @jimstanp

    • Contributors JP and WPK analysed the data. All authors contributed to writing the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.